Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Rhea-AI Summary
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 36-week tissue health and symptom results for the highest dose cohort (Cohort 9) in its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis.
Cohort 9 (n=3) showed a 90% EoEHSS Stage reduction, 88% Grade reduction, 72% PEC reduction, and 66% clinical remission maintained from week 8 through week 36. No drug-related SAEs or cases of oropharyngeal candidiasis were reported across 31 patients and >230 patient-months.
Positive
- EoEHSS Stage reduction of 90% at week 36
- EoEHSS Grade reduction of 88% at week 36
- Peak eosinophil count −72% versus baseline (largest among cohorts)
- Clinical remission maintained in 66% (2 of 3) through week 36
- No drug-related SAEs reported across 31 patients
Negative
- Very small efficacy cohort size: n=3 in Cohort 9
- Phase 1b/2a data; placebo-controlled Phase 2b results not yet available
- Safety follow-up limited to 230 patient-months, not large-scale
News Market Reaction – EPRX
In the Apr 21 session, EPRX declined 2.50%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Investor conferences | Positive | +4.7% | Announced participation in two April 2026 investor conferences with a webcasted presentation. |
| Mar 17 | Clinical trial update | Positive | +2.6% | Reported 24-week top-dose RESOLVE data showing SDI remission rates and clean safety profile. |
| Mar 12 | Earnings and funding | Neutral | -1.9% | Q4 2025 net loss with cash of $80.5M and runway supported by February 2026 offering. |
| Feb 20 | Offering closing | Neutral | +4.7% | Closed US$63.2M public offering of shares and pre-funded warrants to fund EP-104GI and R&D. |
| Feb 19 | Offering pricing | Neutral | -0.5% | Priced US$55M cross-border offering of shares and pre-funded warrants at US$7.00. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news — including trial updates and financings — has generally seen EPRX trade in the same direction as the news tone, with positive clinical updates and capital raises met by modest gains or contained pullbacks.
Over the past few months, Eupraxia has combined clinical progress in EP-104GI with balance sheet strengthening. February’s offerings raised about US$63.2M, followed by Q4 2025 results highlighting $80.5M cash and expected funding into 2H 2028. Clinical RESOLVE data on March 17 showed meaningful symptom improvements with good safety, and investor conference participation in April 2026 supported visibility. Today’s 36‑week highest‑dose data extends this positive clinical trajectory with longer-duration tissue and symptom outcomes.
Key Terms
eosinophilic esophagitis medical
serious adverse events medical
oropharyngeal candidiasis medical
Peak Eosinophil Count medical
Phase 1b/2a medical
placebo-controlled medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial.
- At 36 weeks, patients in Cohort 9 (n=3) demonstrated a robust response in both tissue health and symptom response compared to their baseline levels.
- Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the RESOLVE trial.
- Clinical remission in symptoms was maintained in
66% of the patients (2 of 3) in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks. - EP-104GI continues to be well tolerated by patients receiving the drug; 31 patients have been treated in the Phase 1b/2a study and over 230 patient-months of follow-up have been reported with no drug related Serious Adverse Events ("SAEs"). There still have been no cases of oropharyngeal candidiasis, a commonly reported adverse event with the oral delivery of steroids.
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE").
"We are very pleased with the robust and sustained response in both tissue health and symptom data in the highest dose cohort at 36 weeks,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI. We are also reassured by the excellent safety outcomes across all doses in the trial as we continue to observe no indication of drug related SAEs or spikes in glucose or cortisol. We look forward to the results of the placebo-controlled Phase 2b portion of the study where the same dose is being further evaluated”.
Key New Findings from the RESOLVE Trial
Tissue Health Outcomes as Measured by EoEHSS and PEC
- In Cohort 9 (20 x 8 mg dose) the EoEHSS Stage and Grade reductions at week 36 were 0.59 and 0.53, representing a
90% and88% reduction, respectively. - Notably, improvements were seen across both inflammatory and architectural (i.e. structural) components that comprise the EoEHSS score, suggesting improvements in both inflammatory and fibrotic histologic aspects of the disease.
- Also in Cohort 9 at week 36, there was a
72% reduction in Peak Eosinophil Count (PEC) from baseline. Compared to all other dose cohorts, this was the largest reduction in PEC.
Clinical Remission and Symptom Response as Measured by SDI
- In Cohort 9, at week 36 there was an average reduction compared to baseline in the Straumann Dysphagia Index (SDI) of 3 points (a 3-point reduction is defined as clinical remission).
- In total, 2 of 3 patients maintained clinical remission from weeks 8 to 36, representing a
66% clinical remission response rate.
Safety and Tolerability
- To date, over 230 patient-months of follow-up have been reported across 31 patients in all cohorts.
- No drug related SAEs have been reported.
- No cases of oropharyngeal candidiasis, a commonly reported adverse event associated with the use of swallowed steroids, have been reported.
- No cases of adrenal insufficiency or glucose derangement, including in the single patient with type II diabetes.
- EP-104GI has been generally well tolerated at all dose levels, including the highest dose of 8 mg/site at 20 injection sites (Cohort 9).
An updated summary of the above and previously announced clinical trial results are posted in the Investor Section of the Eupraxia Pharmaceuticals website and can be found here.
About the RESOLVE Trial
The Phase 1b/2a part of the RESOLVE trial is a multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically confirmed active EoE. The treatment is administered as a single dose via 4 to 20 esophageal wall injections, with dose escalations modifying either the dose per site and/or the number of sites. Participants were followed for up to 24 weeks in Cohorts 1-4 (4x1mg, 8x1mg, 8x2.5mg and 12x2.5mg) or 52 weeks in Cohorts 5-9 (12x4mg, 16x4mg, 20x4mg, 20x6mg and 20x8mg). Eupraxia plans to disclose additional data from the open-label Phase 1b/2a part of the RESOLVE trial in the coming months.
The Phase 2b part of RESOLVE trial, a randomized placebo-controlled study of EP-104GI, is currently recruiting both the 120mg (20x6mg) and 160mg (20x8mg) doses. The top-line data from the Phase 2b part of the RESOLVE trial is expected in Q4 2026.
Notes
- Clinical remission is defined as a reduction of at least 3 points on the SDI scale. Achieving clinical remission is a positive outcome for the RESOLVE trial.
- SDI is a patient-reported outcome score that uses a seven-day recall measuring dysphagia (trouble swallowing) severity and frequency. A reduction in SDI is a positive outcome for the RESOLVE trial.
About Eosinophilic Esophagitis (EoE)
EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview Healthcare Partners, EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental health issues, compounding the disease burden of EoE for both the healthcare system and the individual.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.
Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", “indicates”, "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the interpretation of the 36-week data from the RESOLVE trial, including tissue health and symptom response; the Company’s expected timing of reporting additional data from the RESOLVE trial, including the Phase 2b portion thereof; the Company's product candidates, including their expected benefits with respect to safety, tolerability, efficacy and duration of effect and their potential use in therapeutic areas beyond pain and inflammatory gastrointestinal disease; the expectations regarding the advancement of the Company’s product candidates through clinical development; the results of clinical trials of the Company's product candidates; the potential for the Company’s technology to impact the drug delivery process; the potential market opportunity for the Company’s product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the possibility that the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the possibility that the Company's technology may not be successful for its intended use; the fact that the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the possibility that the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the possibility that the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the possibility that the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the fact that the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the fact that the Company relies on external contract research organizations to provide clinical and non-clinical research services; the possibility that the Company may not be able to successfully execute its business strategy; the fact that the Company will require additional financing, which may not be available; the fact that any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236-330-7084
jmeikle@eupraxiapharma.com
or
Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617-283-2856
kgardner@lifesciadvisors.com
SOURCE Eupraxia Pharmaceuticals Inc.
